| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) shares are falling Friday. The company released a presentation on KYV-101, its CD19 CAR T-cell candidate.
The Details:
Kyverna hosted an industry symposium Friday at EULAR in Vienna with a data update on KYV-101, its lead CAR T-cell therapy candidate. The company said it is the largest and most diverse set of data to date from a cohort of 50 patients treated with the CAR in KYV-101, an autologous, fully human anti-CD19 CAR T-cell immunotherapy.
Kyverna went public in February with 14.5 million shares priced at $22 and opened for trading at $34.25 per share. Kyverna shares have lost more than 68% since its IPO.
According to data from Benzinga Pro, 12.28% of available Kyverna shares are being sold short which can lead to large price movements when combined with heavy trading volume.
Related News: What’s Going On With Longeveron Stock?
Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
For example, in Kyverna Therapeutics' case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
KYTX Price Action: According to Benzinga Pro, Kyverna Therapeutics shares are down 35.5% at $9.32 at the time of publication Friday.
Image: Kazun from Pixabay
Posted In: KYTX
